• Home
    • Leucémie myéloïde chronique
    • Leucemia Mieloide Crónica
  • CML Experts
    • Team of experts on CML who developed imatinib >
      • Dr. Elisabeth Buchdunger
      • Dr. Brian Druker
      • Dr. John Goldman
      • Dr. Carlo Gambacorti-Passerini
      • Dr. Nora C. Heisterkamp
      • Dr. David Hungerford
      • Dr. Nicholas Lydon
      • Dr. Alex Matter
      • Dr. Felix Mitelman
      • Dr. Peter C. Nowell
      • Dr. Moshe Talpaz
      • Dr. Janet D. Rowley
      • Dr. Charles Sawyers
      • Dr. Jürg Zimmermann
      • Dr. Owen Witte
    • Experts involved in developing dasatinib >
      • Dr. Jagabandhu Das
    • Experts involved in developing nilotinib
    • Other CML experts in America >
      • Other CML experts in Canada >
        • Dr. Sarit Assouline
        • Dr. Lambert Busque
        • Dr. Robert Delage
        • Dr. Connies Eaves
        • Dr. Josée Hébert
        • Dr. Luigina Mollica
        • Dr. Dennis Kim
        • Dr. Pierre Laneuville
        • Dr. Conrad Vincent Fernandez
        • Dr. Isabelle Bence-Bruckler
        • Dr. Jeffrey H Lipton
        • Dr. Mark Hnatiuk
      • Other CML experts in US >
        • Carolyn Blasdel, RN , FNP-BC, OCN
        • Rey Garcia, RN, BSN
        • PATRICIA JAKEL, RN, MN, AOCN
        • Dr. Ravi Bhatia
        • Dr. Jorge E. Cortes
        • Dr. Javier Pinilla-Ibarz
        • Dr. Catriona Jamieson
        • Dr. Arul Chinnaiyan
        • Dr. Michael Deininger
        • Dr. James D. Griffin
        • Dr. Franziska Michor
        • Dr. Frank Giles
        • Dr. Gabriella Hobbs
        • Dr. Elias J. Jabbour
        • Dr. Hagop Kantarjian
        • Dr. Harry P. Erba
        • Dr. Richard A. Larson
        • Dr. Alison Loren
        • Dr. Michael Mauro
        • Dr. Matt Kalaycio
        • Dr. Stephen D. Nimer
        • Dr. Ruben A. Mesa
        • Dr. Susan M. O'Brien
        • Dr. Jerald P. Radich
        • Dr. Ellen K. Ritchie
        • Dr. Karen Seiter
        • Dr. Kendra Sweet
        • Dr. Neil Shah
        • Dr. Richard T Silver
        • Dr. Richard Stone
        • Dr. Raoul Tibes
        • Dr. Sangmin Lee
        • Dr. Bin Zhang
      • Other CML experts in South America >
        • Dr. Michele Bianchini
        • Dra Beatriz Moiraghi
        • Dra. Carla Boquimpani
        • Dr Carolina Pavlovsky
    • Other CML Experts in Europe >
      • CML Expert in Belgium >
        • Pr Gregor Verhoef
      • CML expert in France >
        • Dr. François-Xavier Mahon
        • Dr Aude Charbonnier
        • Dr. Delphine Rea
        • Dr. Gabriel Etienne
        • Dr. Lawrence Legros
        • Dr. Marie-Joëlle Mozziconacci
        • Pr. Mauricette Michallet
        • Dr. François Guilhot
        • Dr Françoise Huguet
        • Dr. Stéphane Prost
        • Dr. Philippe Rousselot
        • Dr. Eliane Gluckman
        • Dr. Franck-Emmanuel Nicolini
      • CML expert in Italy >
        • Dr. Chiara Elena
        • Dr. Michele Baccarani
        • Dr. Giuseppe Saglio
      • CML expert in UK >
        • Dr. Jane Apperley
        • Dr. Stephen O'Brien
        • Dr. Georgios Nteliopoulos
        • Dr. Adam Mead
        • Dr. Tessa L Holyoake
      • CML expert in Germany >
        • Dr. Andreas Hochhaus
        • Dr Susanne Saussele
        • Dr. Martin Müller
      • CML expert in Portugal >
        • Dr. Antônio Medina de Almeida
      • CML expert in Spain >
        • Dr. Juan Luis Steegmann
      • CML expert in Netherlands >
        • Dr. Jeroen J.W.M. Janssen
      • CML expert in Sweden >
        • Dr. Johan Richter
      • CML expert in Czech Republic >
        • Dr. Hana Klamova
    • Other CML experts in Asia >
      • Dr. Charles Chuah
      • Dr. Goh Yeow Tee
      • Dr. Pankaj Malhotra
      • Dr. Uday Yanamandra
      • Dr. Hemant Malhotra
      • Dr. Kim Dong-Wook
    • Other CML experts in Africa >
      • Dr. Anthony Oyekunle
    • Other CML experts in Australia >
      • Dr. Ilaria Pagani
      • Dr. Susan Branford
      • Pr Tim Hughes
      • Dr. David T. Yeung
      • Dr. Liu Lu
      • Dr. Naranie Shanmuganathan
      • Dr. Anthony P Schwarer
  • Medical Concepts
    • Introduction to CML >
      • Precision medicine in chronic myeloid leukemia
      • Philadelphia chromosome
      • BCR-ABL Transcripts
      • Sokal, Hasford, and EUTOS scores
    • General concepts >
      • Blood
      • Bone Marrow
      • DNA
      • Stem Cells
      • Immune System >
        • Natural killer cell - NK
        • T Cells
      • Blood-Brain Barrier
    • Clinical Trials
    • Treatment response in CML
    • Resistance to treatment in CML >
      • Molecular monitoring in CML >
        • Polymerase Chain Reaction
        • Dr. Kary Bank Mullis
      • Non-adherence of CML patients
      • Sensitive detection of BCR-ABL1 mutations
      • JAK2 Gene
    • Donor lymphocyte infusion (DLI)
    • Interferon regulatory factor 8 (IRF8)
    • Myeloproliferative disorders (MPD) >
      • Introduction to CML
      • Essential Thrombocythemia (ET)
      • Myelofibrosis (MF)
      • Polycythemia Vera (PV)
    • Types of leukemia >
      • Atypical chronic myeloid leukemia
  • Medication
    • Hydroxyurea
    • Interferon Alpha
    • Gleevec (Imatinib) >
      • Generic Imatinib
    • Tasigna (Nilotinib) >
      • Generic nilotinib
    • Sprycel (Dasatinib) >
      • Generic Dasatinib
    • Bosulif (Bosutinib)
    • Iclusig (Ponatinib)
    • Supect (Radotinib)
    • ABL001 (Asciminib)
    • Synribo (Omacetaxine )
    • Jakafi (Ruxolitinib)
    • Flumatinib
    • (Bafetinib)
    • (Danusertib)
    • (Rebastinib)
    • BGB324
    • PF-114
    • NEV-801
    • BP1001
    • HQP1351 (Olverembatinib)
    • K0706
    • ​ S116836
    • Vidaza (Azacitidine)
  • Managing side effects
    • List of side effets >
      • Bone Pain
      • Depression
      • Eyes
      • Ear
      • Fatigue
      • Fluid Retention
      • Gastrointestinal system
      • Hair
      • Heart
      • Hepatotoxicity
      • Kidney
      • Muscle cramping
      • Peripheral Neuropathy in CML
      • Peripheral arterial disease in CML
      • Pleural effusion
      • Pulmonary arterial hypertension
      • Thyroid dysfunction
      • Skin
      • Weight gain
    • CML and Nutrition
    • Food and Drug Interactions
    • Living with CML and diabetes
    • CML and comorbidities
    • Psycho-Oncology
    • Complementary and Alternative Medicine >
      • Art Therapy >
        • Art Therapist
        • CMLer's portofolio
      • Music therapy >
        • YouTube creation by CMLer's family
        • Relaxing Music for Stress Relief. Calm Music for Meditation, Sleep, Healing Therapy, Spa
        • Debussy – Relaxing music - Clair de lune et autres...
        • Delicate music for the soul and LIFE, and birdsong soothes the nervous system.
        • Adagio for Strings (Samuel Barber)
        • Amélie Soundtrack ♥ Comptine d'Un Autre Été
      • Yoga
      • Physical Activity
      • Zootherapy
  • Patient Testimonials
    • 30 years and plus survivors >
      • Mark Popadick
      • Mary Sullivan
      • Tom Strodl
      • Dr. Robert Patenaude -E
      • Skip Duffe
    • 20 years and plus survivors >
      • Doug Jenson
      • Joannie Clements
      • Mel Mann
      • Kevin Williams
      • Rich Jones
      • Tanja Fajon
      • Tamera Simonson
      • Virginia Garner
    • 10 years and plus survivors >
      • Jan Geissler
      • Mary Jane Bertram
      • Pat Elliott
      • Tegan Kubler
      • Jo'story
      • Rob Shick
      • Gary Gonzales
      • Hans Loland
      • Drew Johnston
      • Erin Havel (Author)
      • Sohag
      • Erin Zammett Ruddy
      • Kayla Naton (Pregnancy)
      • Jean McGlynn
      • Tom Cleaver
    • New CMLers >
      • Skye Davidson
      • Amanda Steffy
      • Abbi Evans
      • Alyssa
      • Austin Granatowicz
      • Brown Dudley
      • Nigel
      • Katie
      • Kris
      • Ron Robbecke
    • Some celebrities >
      • How to get the password?
      • Alexa Score
      • Laura Boyd
      • Dr. Richard Rockefeller
      • Ryan O'Neal
      • Tim Holcomb
      • Doris Muramatsu
      • Charlie Schlatter
      • Kareem Abdul-Jabar
      • Kelvin Alston
      • Carlos Carrasco
      • Jason Blake
      • Brian Boyle
      • Roman Reigns
      • Rick Upchurch
    • Suzan Mc Namara and the petition
    • Bud Romine - the first patient
    • Other testimonials
    • Blogs >
      • Blog recently updated >
        • Access CML Drugs
        • Living with CML
        • Michelle D's Blog
        • Jon's Blog
        • Justin Ozuna's Blog
        • Trey's CML Leukemia Blog
      • Blog not recently updated >
        • CMKID's blog – Dislodging the bullet - 2012
        • CML Recovery - Stopping KTI -2011
        • Hans's Blog -2012
        • Elizabeth's Blog - my leukemia - 2013journey
        • Elizabeth's Blog - Heart of the rose -2011
        • Joe's Blog - 2012
        • Josh's Blog - 2014
        • Mannan's Blog -2014
        • Ian's Blog -2014
        • Matt's Blog - 2012
        • Matthew's Blog - 2014
        • Michelle's Blog -2012
        • Nayree's Blog -2011
        • Rob's Blog - 2011
  • Global News on CML
    • English - Latest CML News >
      • News -Archives 2019-2018
      • News - Archives 2017-2016
      • News Archives - 2015-2014
      • News-Archives -2013-2012
      • News - Archives 2011-2001
    • French (Français) - Dernières nouvelles
    • Spanish (Español)-Ultimas noticias
  • Links to other sites, forums and Facebook
    • Sites ( English and other languages)
    • Forums (English and other languages)
    • CML on Facebook (English and other languages)
    • CML on Twitter
    • Audio Podcast
  • Various topics
    • CML patients and the coronavirus
    • You’ve just been diagnosed
    • CML causes
    • Pronostic, life expectancy, quality of life, ..... in chronic myeloid leukemia
    • Increased Risk of Secondary Cancers with CML
    • Vaccination of CMLers
    • CML and pregnancy
    • Children with CML
    • Elderly patients with CML
    • Bone marrow transplant
    • Stem cells from umbilical cord blood
    • CML Blast Crisis treatment
    • Mutation T315I
    • Sports with CML
    • History of CML
    • CML Awareness Day
    • The movie "Dying to Survive"
  • Cure possible for CML?
    • Hematopoietic stem cell transplantation using single UM171-expanded cord blood
    • Combination of tyrosine kinase inhibitor with other medication >
      • Combinaison of hydroxychloroquine with tyrosine kinase inhibitor
      • Combination of ruxolitinib with tyrosine kinase inhibitor
      • Combination of miristen with tyrosine kinase inhibitor
      • Combination of pioglitazone with tyrosine kinase inhibitor
      • Combination of Inecalcitol with tyrosine kinase inhibitor
      • Combination of dasatinib plus Nivolumab
      • Combination of Pembrolizumab with tyrosine kinase inhibitor
      • Combination of interferon with tyrosine kinase inhibitor
      • Combination of Venetoclax with tyrosine kinase inhibitor
    • Inhibitory effect of c-Myc on p53-induced apoptosis in leukemia cells
    • Inhibition of the protein Ezh2 can cure CML?
    • Inhibition of STAT5 in conjunction with standard TKI therapy
    • PROTAC-mediated Targeted Protein Degradation
    • CML vaccine
    • Can immunotherapy cure leukemia?
    • Could fasting cure chronic myeloid leukemia
    • Chimeric Antigen Receptor T-Cell Therapy
    • Can genetic sequencing help to cure leukemia?
    • Can the new drug CX-5461 cure leukemia?
    • CRISPR-Cas9 gene-editing technique
    • Presence of bcr abl fusion transcripts in healthy individua
    • Math could help cure leukemia
    • Natural Medicine >
      • Possible cure for CML in Fish Oil
      • Betel leaf may help fight CML
      • Feverfew extract (parthenolide)
      • Can dandelions kill cancer?
      • Can curcumin cure leukemia?
  • Treatment free remission(TFR)
    • The French trial called STIM (Stop Imatinib)
    • De-escalation of treatment
    • Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients
  • Educational videos
    • Educational videos (in English)
    • Educación de vídeos en español (in Spanish)
    • Vidéos pédagogiques en français (in French)
  • Educational events
  • CML Glossaries
  • Moral Support
    • Where to get help and support
    • Family support
    • Dances at the Cancer Research Centre
    • I Had Cancer: You are not alone
    • I’m A Doctor With Chronic Illness. Here Are 12 Things I Wish People Knew
    • 23 Nice Things You Can Do for Someone With Cancer
    • Stronger
    • The march toward healing
    • Be happy
  • Congresses, conferences, meetings ASH, ASCO, EHA ...
    • ASCO - American Society of Clinical Oncology >
      • ASCO 2020 - Chicago
      • ASCO 2019 - Chicago
      • ASCO 2018 - Chicago
      • ASCO 2017 - Chicago
      • ASCO 2016 - Chicago
      • ASCO 2015 - Chicago
      • ASCO 2014 - Chicago
      • ASCO 2013 - Chicago
      • ASCO 2012 - Chicago
      • ASCO 2011 - Chicago
      • ASCO 2010 - Chicago
    • ASH - American Society of Hematology >
      • ASH 2020 - Virtual
      • ASH 2019- Orlando
      • ASH 2018 - San Diego
      • ASH 2017 - Atlanta
      • ASH 2016 - San Diego
      • ASH 2015 - Orlando
      • ASH 2014 - San Francisco
      • ASH 2013 - New Orleans
      • ASH 2012 - Atlanta
      • ASH 2011 - San Diego
      • ASH 2010 - Orlando
      • ASH 2009 - New Orleans
    • BTG - Bridging the Gap >
      • BTG2019 - Fuzhou - China
      • BTG2018 - Seoul, Korea (South)
      • BTG 2011 - Singapore (Singapore)
    • CML & MPDs - UK National Meetings
    • CML Horizons >
      • CML Horizon 2019 - Lisbon - Portugal
      • CML Horizon 2018 -Warsaw (Pologna)
      • CML Horizon 2017- Frankfurt (Germany)
      • CML Horizon 2016 - Ljubljana (Slovenia)
      • CML Horizons 2015 - (Barcelona, Spain)
      • CML Horizons 2014 - ( Belgrade, Serbia)
      • CML Horizons 2013 - (Prague - Czech Republic)
      • CML Horizons 2012 - (Munich, Germany)
      • CML Horizons 2011 - (Amsterdam - The Netherlands)
    • EHA - European Hematology Association >
      • EHA 2020 - Frankfurt,Germany(
      • EHA 2019 - Amsterdam (Netherlands)
      • EHA 2018 - Stockholm(Sweden)
      • EHA 2017 - Madrid (Spain)
      • EHA2016-Copenhagen,(Denmark)
      • EHA 2015 - Vienne (Austria)
      • EHA 2014 - Milan (Italy)
      • EHA 2013 - Stockholm (Sweden)
      • EHA 2012 - Amsterdam (The Netherlands)
      • EHA 2011 - London (England)
      • EHA 2010 - Cascais (Portugal)
      • EHA 2009 - Berlin (Germany)
      • EHA 2008 - Copenhague (Danemark)
    • ESH - European School of Haematology >
      • ESH 2020 - Mandelieu-La Napoule, -France
      • ESH 2019 - Bordeaux - France
      • ESH 2016 - Houston - USA
      • ESH 2015 - Estoril - Portugal
      • ESH 2014 - Philadelphia
  • Professionnel help and literature
    • Dr. Siddhartha Mukherjee
  • Patient Rights
  • New technological advances
  • International publications
    • Publications from Africa
    • Publications from America
    • Publications from Australia
    • Publications from Asia
    • Publications from Europe
  • Specialist Journals in Hematology/Oncology
  • Foundations
    • Leukemia Foundations >
      • American Cancer Society
    • Hospital Foundations
  • Awards & Recognition
  • Private group registration
    • Membership registration - CMLeukemia private group
    • Enregistrement des membres - Groupe privé CMLeukemia
    • Registro de membresía - CMLeucemia grupo privado
  • DONATE
  • About us
    • Our mission
    • Total access on the website - membership
  • Contact us
Chronic Myeloid Leukemia

Bosulif® (Bosutinib) - Chronic Myeloid Leukemia

​
Bosulif® (Bosutinib) is a third generation tyrosine kinase inhibitor. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis (cell death). Responses were seen across Bcr-Abl mutations, including those associated with dasatinib and nilotinib resistance, except T315I.


​See also the List of side effects 
​
SITES

Bosulif® (Bosutinib) by Pfizer.com
Bosulif® (Bosutinib) for Professionels  by  Pfizer.com​
CLINICAL TRIALS

Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
October 2018,  ClinicalTrial.gov

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
August 2017, ClinicalTrial.gov​

Bosutinib in Elderly Chronic Myeloid Leukemia (BEST)

BCHILD - Bosutinib in Pediatric Patients [Denmark, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, Switzerland, UK]
                         All clinical trials with bosutinib
VIDEOS  

Bosutinib: a new, safer TKI for frontline CML (Dr. Michael Mauro)
August 15, 2018, VJHemOnc – Video Journal of Hematological Oncology


Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment   
December 18, 2017, 
OBRoncology

Comparing Bosutinib Versus Imatinib in Newly Diagnosed CML (Dr. Jorge Cortes)
June 5, 2017, Targeted Oncology


What are the efficacy and safety considerations of bosutinib therapy? (Dr. Neil P. Shah)
April 29, 2016, MediCom Oncology


Bosutinib in the Second-Line Setting (Elias Jabbour, MD)
February 24, 2015, OncLiveTV


Dr. Shapiro Discusses Bosutinib in CML            
December 23, 2013, OncLIve

Bosutinib as a treatment for newly diagnosed chronic myeloid leukaemia  (Prof Carlo Gambacorti-Passerini ) 
February 18, 2011,
ecancerTV

ARTICLES   
​​​​
Trial Data Highlight Safety and Efficacy of Bosutinib for Chronic-Phase CML
July 21, 2020, Oncology Learning Network


Pregnancy outcomes in patients treated with bosutinib
May 29, 2020, PubMed

​
Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia
April 11, 2020, 
PubMed

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors
December 8, 2019, ASH 2019

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study
December 8, 2019, ASH 2019

Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kynase Inhibitors
December 8, 2019, ASH 2019
   
Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study   
December 8, 2019, ASH 2019

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study
December 8, 2019, ASH 2019
 
Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs)
December 8, 2019, ASH 2019

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia
December 8, 2019, ASH 2019

Phase 2 Study of Bosutinib in Japanese Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
December 8, 2019, ASH 2019

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
May 1, 2019, PubMed

Bosutinib: Management of Adverse Events in Chronic Myeloid Leukemia
January 23, 2019, Cancer Therapy Advisor

Bosutinib Protects Against Endothelial Vascular Leakage by Preventing Focal Adhesion Disassembly
2018, ATS Journals


Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
December 27, 2018, NCBI


Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients
December 2, 2018, ASH 2018

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
April 13, 2018, PubMed

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
April 9, 2018,  Dove Medical Press  

Bosutinib Nears EU Approval for Frontline Ph+ CML
February 26, 2018, OncLive

Practical management of toxicities associated with bosutinib  in patients with Philadelphia chromosome-positive chronic myeloid leukemia
January 27, 2018, 
 Annals of Oncology

FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017,  OncLive

Bosutinib in Newly Diagnosed Chronic Myeloid Leukemia (CML): Gastrointestinal (GI), Liver, and Hematological Safety Characterization in the BFORE Trial
​December 2017, 
ASH 2017

Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update
December 2017, 
ASH 2017
 
Long-Term Cardiac, Vascular and Hypertensive Safety of Bosutinib in Patients with Philadelphia Chromosome-Positive (Ph+) Leukemia Resistant or Intolerant to Prior Therapy
December 2017, 
ASH 2017

Optimizing Dose of Bosutinib to Minimize Adverse Events While Maintaining Efficacy in Patients with Newly Diagnosed Chronic Myelogenous Leukemia
December 2017, 
ASH 2017
​
​ 
Bosutinib Safe, Effective in Second and Third Line Among Patients With CML
October 27, 2017, Cancer Therapy Advisor

Trial Compares Bosutinib and Imatinib for First-Line CML Rx
September 21, 2017, Clinical Oncology News

Bosutinib Distinguishes Itself as Potential Option for Newly-Diagnosed CML
September 15, 2017, Targeted Oncology

Frontline bosutinib 'an option' for newly diagnosed CP CML
June 22, 2017, MedwireNews

Bosutinib vs Imatinib for First-line Chronic Myeloid Leukemia Treatment
June 7, 2017, Cancer Therapy Advisor

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias        **** WARNING  ***
June 2017, Clinical  Lymphoma, Myeloma and leukemia

Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment
April 13, 2017, PubMed

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
February 9, 2017, OncolyNurseAdvisor

Efficacy and Safety Following Bosutinib Dose Reduction in Patients with Philadelphia Chromosome‒Positive Chronic Myeloid Leukemia
December 2016, ASH 2016

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment
December 2016, ASH 2016

Bosutinib Offers Long-Term Efficacy in CML Patients Who Failed TKI Therapy
November 23, 2016, Cancer Network

Bosutinib for CML After Progression With First-line TKI
November 10, 2016, Cancer Therapy Advisor  


Long-term later-line bosutinib benefits CML patients
October 18, 2016, medwireNews

Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal

Bosutinib shows 'low' vascular, cardiac event risk profile
April 21, 2016‎, News-Medical.net

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
April 12,2016, Europe PMC


Positive bosutinib response for elderly blast phase CML patient
January 22, 2016,  News-Medical.net

Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib
December 7, 2015, ASH 2015

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
December 6, 2015, ASH 2015

Study Assesses Factors Influencing Bosutinib Efficacy, Safety in CML
November 5, 2015, Oncology Nurse Advisor

Bosutinib is well-suited for older patients with chronic myeloid leukemia
July 3, 2015,  Medical News Today


Long-term Bosutinib in patients with chronic phase  CML after prior  imatinib failure
June 2015,  EHA 2015

Long-term evaluation of vascular toxicity in patients with Ph+ leukemias treated with bosutinib
June 2, 2014, 2014 ASCO Annual Meeting

Bosutinib safety and management of  toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
December 17, 2013,
Journal  Blood

Pfizer’s Bosutinib Receives Positive Opinion For Conditional  Marketing Authorization From The Committee For Medicinal Products For Human Use  For The Treatment Of Ph+ Chronic Myelogenous Leukemia With Resistance Or  Intolerance To Prior Therapy In Europe
January 18, 2013,  Pfizer Press  Releases

Pfizer's Bosulif set for greater sales with EMA  approval
January 18, 2013, Fierce Pharna

Pfizer,  Novartis win EU nods for new leukemia, eye  drugs
January 18, 2013, FierceBiotech

Bosutinib a New Option for Chronic Myeloid Leukemia
December 2012, Clinical Oncology

FDA approves orphan drug for CML
October 1, 2012, HemOnc Today

FDA Approves Bosutinib (Bosulif) for Chronic Myeloid Leukemia (CML)
September 5, 2012, Cancer Network

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
September 4, 2012, PubMed

Bosutinib Achieves Faster Response Rates in Newly Diagnosed Chronic Phase CML Patients Than Imatinib
June 3 , 2011, Monthly Prescribing Reference

STUDY 200: Study Evaluating Bosutinib in Philadelphia Chromosome Positive Leukemia
June 3, 2011, Pfizer Oncology

Pfizer Plans Regulatory Submissions Of Bosutinib In Chronic Myeloid Leukemia
December 3, 2010, Pfizer Oncology
​
          (See our disclaimer - Voir notre avis de non-responsabilité- Vea nuestro descargo de responsabilidad)
​
        Privacy Policy   
                    
Copyright © 2010-2021 CMLeukemia.com
Protected by Copyscape     DMCA.com Protection Status